Author:
Sailstad J. M.,Amaravadi L.,Clements-Egan A.,Gorovits B.,Myler H. A.,Pillutla R. C.,Pursuhothama S.,Putman M.,Rose M. K.,Sonehara K.,Tang L.,Wustner J. T.
Publisher
Springer Science and Business Media LLC
Reference64 articles.
1. Food and Drug Administration. Guidance for industry: bioanalytical method validation. Rockville, MD: US Department of Health and Human Services, FDA, Center for Drug Evaluation and Research. 2001.
2. European Medicines A. Guideline on bioanalytical method validation. London: Committee for Medicinal Products for Human Use (CHMP); 2011.
3. Shah VP, Midha KK, Digh S, McGilveray IJ, Skelly JP, Yacobi A, et al. Analytical methods validation: bioavailibility, bioequivalence, and pharmacokinetic studies. J Pharm Sci. 1992;81:309–12.
4. Roskos LK, Schneider A, Vainshtein I, Schwickart M, Lee R, Lu H, et al. PK–PD modeling of protein drugs: implications in assay development. Bioanalysis. 2011;3(6):659–75.
5. Lee JW, Kelley M, King LE, Yang J, Salimi-Moosavi H, Tang MT. Bioanalytical approaches to quantify “total” and “free” therapeutic antibodies and their targets: technical challenges and PK/PD applications over the course of drug development. AAPS J. 2011;13(1):99–110. doi: 10.1208/s12248-011-9251-3 .
Cited by
53 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献